Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts ...

Our teaching excellence feeds into a fantastic array of undergraduate degrees in a variety of subjects, while our ground-breaking research has led to: new treatments for ovarian cancer, the discovery ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on ...

Sai Life Sciences Ltd.'s shares rose after Morgan Stanley initiated coverage citing cost advantage, infrastructure, and global supply chain diversification. The company is one of India's largest ...

In March, Nirma acquired 91,895,379 equity shares, representing 75% of the current issued and paid-up equity share capital of Glenmark Life Sciences from Glenmark Pharmaceuticals. Under the terms of ...

Thank you for signing up! Did you know with a Digital Subscription to The Star, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads ...